Iridex study finds sustained glaucoma benefits from MicroPulse laser therapy
Iridex announced on October 12, 2026, that a retrospective study of its MicroPulse transscleral laser therapy followed 53 patients contributing 84 eyes for two years. Mean intraocular pressure fell from 22.32 mmHg to 14.05 mmHg, while average topical medication use declined from 2.96 to 2.38. The study found treatment success in 86% of primary open-angle glaucoma eyes and 81% of primary angle-closure glaucoma eyes, with no reported complications or loss of visual acuity during follow-up.
Why it matters
The publication provides clinical outcome data for Iridex’s glaucoma treatment platform. Iridex said the results add to evidence supporting MicroPulse therapy, while the study’s lead author said they indicate potential use earlier in the glaucoma treatment process.
Key facts
- 1The retrospective study covered 84 eyes contributed by 53 patients with primary open-angle or primary angle-closure glaucoma. stocktitan.net
- 2At 24 months, mean IOP declined from 22.32 mmHg to 14.05 mmHg. stocktitan.net
- 3Average topical IOP-lowering medication use decreased from 2.96 to 2.38. stocktitan.net
- 4Treatment success was 86% for primary open-angle glaucoma eyes and 81% for primary angle-closure glaucoma eyes. stocktitan.net
- 5Patients taking oral acetazolamide before treatment stopped using it, and none restarted it during the two-year follow-up. stocktitan.net
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.